In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angiotech's resorbable sutures:

This article was originally published in Clinica

Executive Summary

Angiotech Pharmaceuticals has received 510(k) clearance from the US FDA for its resorbable sutures product line - Quill SRS Monoderm. The products, part of the company's larger "Quill" range of self-retaining system (SRS) sutures, are made from a rapidly absorbing polymer, and are indicated for use primarily in superficial wound closure. The Vancouver, Canada firm hopes to launch the product line in the US this autumn. The Quill SRS range of sutures incorporates a patented helical barbed design which obviates the need to tie knots to hold sutures in place. Angiotech also gained 510(k) clearance to market additional diameters of its Quill SRS Polydioxanone (PDO) product line - longer-lasting absorbable sutures typically used for deeper tissue closure.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts